NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854
(titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily
for the treatment of Tardive Dyskinesia (TD) symptoms.